Neutrophil Recruitment After EBC-46 Injection: How Tigilanol Tiglate Mobilises Innate Immunity

Tigilanol tiglate (EBC-46) is usually described in terms of its direct effect on tumour vasculature and membrane integrity, but a second mechanism has become increasingly visible in published preclinical data: rapid recruitment of innate immune cells, particularly neutrophils, to the injection site within hours of treatment.

The neutrophil wave

Work published by the QBiotics research group and independent academic laboratories describes a characteristic sequence of events following intratumoral tigilanol tiglate. Vascular disruption happens early — within minutes — producing localised haemorrhage and endothelial dysfunction. Over the subsequent hours, neutrophils infiltrate the treated area in large numbers, followed later by macrophages and other effector populations. This pattern has been captured in histological analyses from veterinary canine trials and in rodent xenograft models.

PKC activation and DAMP release

Why do neutrophils arrive so rapidly? Two related signals appear to drive the response. First, tigilanol tiglate activates classical and novel protein kinase C (PKC) isoforms through diacylglycerol (DAG) mimicry. PKC signalling in endothelial and stromal cells triggers release of neutrophil chemoattractants such as CXCL1 and CXCL8 (IL-8).

Second, the mechanical disruption of tumour cells releases damage-associated molecular patterns (DAMPs) — including HMGB1, uric acid, and ATP — which engage pattern-recognition receptors on resident innate immune cells. A review of the innate immune response to cytolytic anticancer agents places tigilanol tiglate alongside other PKC activators that drive this kind of sterile inflammation.

Why the innate response matters

Neutrophils are often cast as a non-specific nuisance, but in the tumour context their role can be constructive. Activated neutrophils clear apoptotic and necrotic debris, release reactive oxygen species that kill compromised tumour cells, and produce cytokines that bridge to the adaptive immune system. The biopsy data from tigilanol tiglate human trials shows exactly this kind of remodelling — early infiltration of polymorphonuclear leucocytes, followed by a more organised immune architecture in healing tissue.

Bridging to adaptive immunity

What happens after the initial neutrophil wave is arguably more interesting from a long-term biology standpoint. As neutrophils clear debris, they release mediators that recruit monocytes and dendritic cells. Dendritic cells, in turn, sample tumour-derived antigens and migrate to draining lymph nodes where they can prime T-cell responses. The degree to which this bridging to adaptive immunity is clinically meaningful with tigilanol tiglate remains under active investigation, but biopsy analyses from treated human tumours have reported increased CD8+ T cell presence at resolved injection sites, consistent with this narrative.

Cytokine patterns and timing

Cytokine profiling in preclinical models shows a characteristic early spike of pro-inflammatory mediators — notably IL-1β, IL-6, and TNF-α — followed by a resolution phase involving IL-10 and TGF-β. This pattern is similar to what is observed in other forms of sterile necrotic injury, and it is important for understanding why wound healing typically proceeds in an orderly fashion rather than becoming chronically inflamed. The general review of neutrophil functions in inflammation resolution helps place these observations in the broader immunology literature.

A distinct mechanism from pure cytotoxicity

Conventional chemotherapy generally suppresses haematopoiesis and reduces circulating neutrophil counts. Tigilanol tiglate does the opposite at the injection site — it concentrates neutrophils locally. This distinction is one reason the compound is often described as an intratumoural cytotoxic and immunomodulatory agent rather than a classical cytotoxic drug.

What this means for supplement readers

These mechanistic findings come from preclinical and veterinary research on pharmaceutical-grade tigilanol tiglate administered intratumorally. They do not translate to oral dosing of blushwood berry extract supplements, which do not deliver isolated tigilanol tiglate and are not intended to diagnose, treat, cure or prevent any disease. Consumer products such as Blushwood Health’s blushwood berry extract are dietary supplements whose role is nutritional, not therapeutic. Understanding the underlying immunology nonetheless helps contextualise why researchers continue to study this compound.

Related Articles

Further mechanism reading: Cytolytic Cascade: How EBC-46 Triggers Membrane Disruption, VEGF Suppression and EBC-46, and Calcium-Dependent PKC Activation by EBC-46.